Skip to main content

Table 3 Study primary and secondary endpoints. Data are expressed as mean (SD), unless otherwise specified

From: Factor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial

Variable FEIBA
n = 6
Placebo
n = 6
Difference (95% confidence interval)
Volume of all blood products transfused, mL 3126 (3710) 2227 (3710) −899 (−5205.7 to 3408.7)
Blood product transfused intraoperatively
 Packed red blood cells, n (%) 4 (67) 0 (0)  
 Packed red blood cells, mL 572 (552) 0 (0) −572 (−1073.7 to −69.6)
 Fresh-frozen plasma, n (%) 4 (67) 4 (67)  
 Fresh-frozen plasma, mL 981 (857) 338 (288) −643 (−1465.2 to 179.2)
 Platelets, n (%) 6 (100) 5 (83)  
 Platelets, mL 952 (511) 437 (308) −515 (−1057.2 to 27.2)
 Cryoprecipitate, n (%) 3 (50) 0 (0)  
 Cryoprecipitate, mL 171 (210) 0 −171 (−362.2 to 20.2)
Blood product transfused in the ICU
 Packed red blood cells, n (%) 1 (17) 1 (17)  
 Packed red blood cells, mL 175 (429) 572 (1400) 397 (−935.4 to 1728.8)
 Fresh-frozen plasma, n (%) 1 (17) 1 (17)  
 Fresh-frozen plasma, mL 102 (250) 437 (1070) 335 (−664.7 to 1333.7)
 Platelets, n (%) 1 (17) 1 (17)  
 Platelets, mL 49 (119) 83 (204) 35 (−179.8 to 249.2)
 Cryoprecipitate, n (%) 1 (17) 1 (17)  
 Cryoprecipitate, mL 21 (51) 79 (194) 58 (−123.9 to 240.2)
Patients requiring re-exploration, n (%) 1 (17) 1 (17)  
Chest tube drainage at 8 h, mL 282 (110) 611 (860) 329 (−459.3 to 1117.3)
Chest tube drainage at 24 h, mL 725 (559) 913 (1028) 188 (−876.1 to 1252.4)
ICU intubation, hours 87.2 (162.6) 8.2 (6.2) −79 (−249.6 to 91.6)
Length of ICU stay, hours 333.5 (670.7) 74.3 (51.1) 259.2 (−962.7 to 444.4)
Length of hospital stay, days 20.3 (25.7) 5.7 (1.0) 14.7 (−41.6 to 12.3)
  1. FEIBA, factor eight inhibitor bypass activity; ICU, intensive care unit